|
|
| Friday, 16 April, 2010 |
| 08h30-10h30 |
Session I - Hematopoietic Stem Cell (HSC) Therapies - Chair: F. Locatelli (Pavia) |
|
| |
Allogeneic BMT in Sickle cell anemia |
F. Bernaudin (Créteil) |
| |
Hematopoietic stem cell therapy for thalassemias |
S. Hongeng (Bangkok) |
| |
New Trends in HSC therapies |
F. Locatelli (Pavia) |
| |
Panel Discussion |
|
| Selected oral presentations (15 min each) |
| 10h30 - 11h00 |
Coffee break |
|
| 11h00-13h00 |
Session II - From HSC to Erythocyte - Chair: F. Grosveld (Rotterdam) |
|
| |
Expansion of HSCs |
K. Humphries (Vancouver) |
| |
The molecular switching in erythroid differentiation |
S. Orkin (Boston) |
| |
Programming the hemoglobin genes for therapies |
F. Grosveld (Rotterdam) |
| |
Overcoming insertional adverse events of integrating gene vectors |
C. Baum (Hannover) |
| 13h00 - 13h00 |
Lunch |
|
| 15h00- 17h30 |
Session III - Gene Therapy - Chair: P. Leboulch (Fontenay/Boston) |
|
| Selected oral presentations (15 min each) |
| |
Gene Therapy of hemoglobin disorders |
Ph. Leboulch (Fontenay/Boston) |
| |
Design of lentiviral vectors |
C. Frecha (Lyon) |
| |
Oncogenic safety |
C. Baum (Hannover) |
| Selected oral presentations (15 min each) |
| 17h30 - 18h00 |
Coffee break |
|
| 18h00-19h00 |
Poster Session I: Biotherapies |
|
| |
|
|
| Saturday, 17 April, 2010 |
| 08h30 - 10h30 |
Session IV - Iron regulatory pathway for therapies - Chair: C. Camaschella (Milano) |
|
| |
Heme and Iron recycling |
C. Beaumont (Paris) |
| |
Role of Hemojuvelin in iron deficiency and overload |
C. Camaschella (Milano) |
| |
The essential role of BMP6 in hepcidin regulation |
M.P. Roth (Toulouse) |
| Selected oral presentations (15 min each) |
| 10h30 - 11h00 |
Coffee break |
|
| 11h00 - 13h00 |
Session V - The hepcidin effector pathway for therapies - Chair: C. Beaumont (Paris) |
|
| |
Hepcidin agonists and antagonists |
E. Nemeth (Los Angeles) |
| |
Targeting the hepcidin binding site of ferroportin |
I. de Domenico (Salt Lake City) |
| |
Relocating misdistributed iron chelators |
I. Cabantchick (Jerusalem) |
| Selected oral presentations (15 min each) |
| 13h00 - 15h00 |
Lunch |
|
| 15h00 - 17h30 |
Session VI - Innovative therapies for red cell disorders (I) - Chair: N. Mohandas (New-York) |
|
| |
Predictive factors of severity for therapies of hemoglobin disorders |
S. Fucharoen (Bangkok) |
| |
Erythrocyte acting therapies |
Y. Beuzard (Fontenay) |
| |
Gene activation therapies |
S.L. Thein (London) |
| |
EPO therapy in hemoglobin disorders |
F. Galactéros (Créteil) |
| |
Selected oral presentations (15 min each) |
|
| 17h30 - 18h00 |
Coffee break |
|
| 18h00 - 19h00 |
Poster Session II: Iron and erythrocyte targeting therapies |
|
| |
|
|
| Sunday, 18 April, 2010 |
| 09h00 - 10h00 |
Session VII - Innovative Therapies for red cell disorders (II) - Chair: F. Galacteros (Creteil) |
|
| |
Vascular acting therapies in Sickle cell disease |
P-L. Tharaux (Paris) |
| |
Heme oxygenase protects against red cell disorders |
M. Soares (Lisbon) |
| 10h00 - 10h30 |
Coffee break |
|
| 10h30 - 11h30 |
Keynote Lecture |
|
| |
Erythrocyte targeting for therapies in malaria |
N. Mohandas (New-York) |
| |
|
|
| |
End of the meeting |
|
| |
|
|
| |
|
|
| |